Solazyme: Now, Express Yourself in the oils you choose.

Jim Lane In an on-time arrival, Solazyme starts up at 500,000 liter scale in Clinton, Iowa.  In California, Solazyme (SZYM) announced that commercial operations have commenced at both Archer Daniels Midland Company’s (ADM) Clinton, Iowa facility, and the downstream companion facility operated by American Natural Products in Galva, Iowa. Highlighting the flexibility of Solazyme’s technology platform, Solazyme, ADM and ANP have successfully manufactured three distinct and unique tailored oil products at the facilities, and products are currently being sold and distributed in both the U.S. and Brazil. Volumes shipped to Brazil are being utilized for...

Solazyme Shares Soar On Sasol Deal

Jim Lane Bioenergy’s #1 company surges on the exchanges after big Sasol, AkzoNobel partnership announcements. In California, Solazyme (SZYM) announced a Q2 loss of $25.8M, compared to a Q2 2012 loss of $19.2M, on revenues of $11.2M, down from $13.2M for Q2 2012, as government funded revenues declined as expected. Excluding the government sector, sales jumped 28% year on year despite the lack of the big capacity that Moema and Clinton will represent when completed. Product gross margins were a very healthy 70%, in line with guidance. Solazyme shares were up 12.95 percent today at market close....

Two Thumbs Up for Solazyme: AkzoNobel deal, new technology for structured oils

Jim Lane The sector’s perennial hottest company strikes again with “potentially disruptive” new technology to change the positioning and performance of triglyceride oils. In California, Solazyme (SZYM) and AkzoNobel announced an agreement targeting the development of advanced tailored triglyceride oils and commercial sales for near-term product supply. The agreement focuses on supply for the chemical giant’s Surface Chemistry and Decorative Paints businesses. Commercial supply of multi-thousand ton quantities of highly sustainable algal oil is expected to originate from the Solazyme Bunge Renewable Oils Joint Venture oil manufacturing plant in Brazil. Sales of product are anticipated to commence...

BioAmber Completes IPO

Jim Lane Raises $80M at $10 per share; becomes first new industrial biotech company to complete IPO in more than a year. What went right and how? Is the IPO window re-opening? In Minnesota, BioAmber announced the pricing of its initial public offering of 8 million units consisting of one share of common stock and one warrant to purchase half of one share of common stock at $10 per unit, before underwriting discounts and commissions. All units are being sold. BioAmber has granted the underwriters an option for 30 days to purchase up to an additional 1.2 million...

Save 31% on BioAmber’s IPO

Jim Lane Will BioAmber complete its IPO? As the industry waits, fingers crossed, the biosuccinic developer sweetens the pot with warrants, lower share prices. In Canada, BioAmber has reduced the proposed price range for its IPO to $10-$12 per share, down from a $15-$17 range as it seeks to keep the initial public offering on track. Overall, the company now proposes to raise between $80 million and $110.4 million in the offering, now scheduled for May 13th according to the latest calendar from NASDAQ. At the offering’s midpoint and excluding the sale of up...

BioAmber Sets Price Range for IPO

Jim Lane  8 million share offering at $15-$17 aims to raise $128 million. “We are selling 8,000,000 shares of common stock,” begins BioAmber’s latest SEC update, written in IPO-legalese. “The initial public offering price of our common stock is expected to be between $15.00 and $17.00 per share, which is the equivalent of €11.48 and €13.01 per share, based on an assumed Bloomberg BFIX Rate for USDEUR at the pricing of this offering. If completed, it would be the first successful IPO in the sector since Ceres (CERE) and Renewable Energy Group (REGI)...

Biobased and Biofuel Investments: A System

Jim Lane A Biofuels and Biobased investment primer: An 18-combination, 8-character system for classifying bio investments Here’s our investment primer on how to size up the risks and the rewards and tune them to meet your goals. And, a system for organizing opportunities. So, you’re thinking about investing in bio? Here’s the good news – you’re not alone. Here’s the bad news – you’re not alone. There are retail, private equity, hedge fund, sovereign wealth, strategic, grower, VC and institutional investors snooping around too, and making active investments. For one thing, carbon’s making a comeback as the...

Solazyme’s Detours on the Way to Algae Biofuel

by Debra Fiakas CFA Investors who took the time to read my last two posts on algae-based biofuel – “Algae Takes Flight” and “Emission Standards Driving Aviation Fuel Sourcing”  -   might have wondered why there was no mention of Solazyme, Inc. (SZYM:  Nasdaq).  California-based Solazyme has been pursuing algae-based oils for transportation since 2004, and managed to record its first product sales in 2011.  However, that revenue was not from biofuel. On the long road to finding a scalable and efficient way to get renewable fuel from algae, Solazyme scientists found an interesting extract...

The Hocky-Stick Growth of Biobased Intermediates

Super-cali-thali-terpa-butyl-peta what? Jim Lane The new trend in biofuels is not a biofuel at all – it’s an (usually unpronounceable) intermediate that can be refined into an array of fuels, chemicals, flavors, fragrances, and construction or packaging materials. Ptera-buta-thalic-what? We can hardly pronounce them, but we sure need to know about them. Amyris (AMRS), KiOR (KIOR), Renmatix, Virdia, Blue Sugars, Proterro, Sucre Source, Sweetwater Energy, Genomatica – hot companies all, what do they have in common? Instead of making a finished end-product, they make an intermediate which is then upgraded to a finished product, typically...

Jobs at Gevo

by Debra Fiakas CFA Management teams at the helm of public companies often shade the realities of their competitive or strategic situation, alternately painting better circumstances or downplaying declining fortunes.  There are myriad ways of giving management’s guidance a reality check.  Renewable bio-chemicals developer Gevo, Inc. (GEVO:  Nasdaq) is on my “watch list” as one of the more interesting companies in the Beach Boys Index.    Gevo’s financial results missed the consensus estimate in both the March and June 2012 quarters, but management made claims of important victories.  Gevo has won important decisions in the disagreement...

The “Jesus” Molecule: Paraxylene

Jim Lane The Coca-Cola Company invests in Gevo, Virent and Avantium partnerships, in the race to develop renewable plastic bottling entirely from renewables. There’s been an awful lot of press this week about progress in the search for the God particle. That’s the subatomic Higgs Boson a key, but as yet undetected, anchor in the standard model of the universe. Then there’s the Jesus molecule. As in, “Kind lord Jesus in Heaven, grant me an affordable way to make one of those.” It’s renewable PX, also known as your friend, paraxylene a key, but as...

BioAmber’s $150 Million IPO: The 10-Minute Version

Jim Lane A first-to-market leader in bio-succinic acid comes to the public markets with its IPO. Can BioAmber translate a lead in succinic acid’s smallish market into leadership in a vast array of high-priced renewable chemicals? Here’s our 10-minute version of the BioAmber IPO, with a translation of the risks into English. In Minnesota, BioAmber has filed an S-1 registration statement for a proposed $150 million initial public offering. The number of shares to be offered in the proposed offering and the price range for the offering have not yet been determined. The lead book-running managers for...

Elevance’s $100M IPO: The 10-Minute Version

Jim Lane Like to quickly understand the surge in renewable chemicals and one of the hottest companies in the hottest sector of the bioconomy? Here’s our 10-minute version of the IPO from Elevance Renewable Sciences. Complete with the risks, translated into English from the original SEC-speak. In Illinois, Elevance Renewable Sciences filed its S-1 registration statement relating to a proposed $100 million initial public offering. The number of shares to be offered and the price range for the offering have not yet been determined. The company indicated that it has apply to list the stock on NASDAQ under the ERSI symbol. The...